When did iRadimed report Q1 2026 earnings?

iRadimed (IRMD) reported Q1 2026 earnings on May 1, 2026 before market open.

What were iRadimed's Q1 2026 revenue and EPS?

iRadimed reported revenue of $22.0M and eps of $0.49 for Q1 2026.

Did iRadimed beat estimates in Q1 2026?

Revenue beat the consensus estimate of $21.3M by $664.0K. EPS beat the consensus estimate of $0.46 by $0.03.

How did iRadimed's Q1 2026 results compare year-over-year?

Compared to the same quarter a year prior, revenue grew 12.7% from $19.5M a year earlier and eps grew 16.7% from $0.42.

Where can I find iRadimed's Q1 2026 SEC filings?

You can read the 8-K earnings release (0001628280-26-029125) and the 10-Q periodic report (0001628280-26-029325) directly on SEC EDGAR. The filing index links above go to sec.gov.

iRadimed IRMD Q1 2026 earnings

Reported May 1, 2026 · Before market open

Revenue$22.0MBeat by $664.0K

EPS$0.49Beat by $0.03

Revenue estimate$21.3M

EPS estimate$0.46

Next report

Jul 31, 2026 (In 2 days)

Revenue estimate$20.4M

EPS estimate$0.42

Financials

Q1 2026

Income statement

See full

Revenue$22.0M+12.6%

Gross profit$16.8M+13.3%

Operating income$7.2M+33.2%

Net income$5.8M+24.1%

EPS (diluted)$0.45+21.6%

Balance sheet

See full

Cash & equivalents$56.4M+12.0%

Total equity$98.5M+9.4%

Total assets$114.4M+12.4%

Cash flow

See full

Operating cash flow$8.3M+93.2%

CapEx$403.0K-89.1%

Free cash flow$7.9M+1,226%

Valuation & ratios

Valuation

as of 07/28/26

See full

Market cap$1.22B+67.4%

P/E51.5×+16.3×

P/S14.1×+4.7×

Profitability

See full

Gross margin76.8%-0.1pp

Operating margin32.4%+2.3pp

Net margin27.4%+1.0pp

FCF margin28.4%+8.9pp

Returns & leverage

See full

Return on equity25%+1.2pp

Current ratio7.1×-1.7×

Segments

By product

See full

MRI Compatible IV Infusion Pumps$7.7M+27.8%

MRI Compatible Patient Vital Signs Monitoring Systems$7.1M+8.6%

Disposables$4.9M—

Services and other$1.0M—

Amortization of extended maintenance agreements$659.0K—

Versus estimates

Revenue

Q1 2026$22.0MBeat by $664.0K

Q4 2025$22.7MBeat by $1.1M Q3 2025$21.2MMiss by $394.9K Q2 2025$20.4MMiss by $89.1K Q1 2025$19.5MBeat by $178.6K Q4 2024$19.4MBeat by $189.2K

Diluted EPS

Q1 2026$0.49Beat by $0.03

Q4 2025$0.54Beat by $0.05 Q3 2025$0.47Miss by $0.01 Q2 2025$0.49Beat by $0.04 Q1 2025$0.42Miss by $0.01 Q4 2024$0.44Miss by $0.01

Ask the moment iRadimed reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI

Claude

Questions, answered.

When did iRadimed report Q1 2026 earnings?: iRadimed (IRMD) reported Q1 2026 earnings on May 1, 2026 before market open.
What were iRadimed's Q1 2026 revenue and EPS?: iRadimed reported revenue of $22.0M and eps of $0.49 for Q1 2026.
Did iRadimed beat estimates in Q1 2026?: Revenue beat the consensus estimate of $21.3M by $664.0K. EPS beat the consensus estimate of $0.46 by $0.03.
How did iRadimed's Q1 2026 results compare year-over-year?: Compared to the same quarter a year prior, revenue grew 12.7% from $19.5M a year earlier and eps grew 16.7% from $0.42.
Where can I find iRadimed's Q1 2026 SEC filings?: You can read the 8-K earnings release (0001628280-26-029125) and the 10-Q periodic report (0001628280-26-029325) directly on SEC EDGAR. The filing index links above go to sec.gov.